|
DE3572982D1
(en)
|
1984-03-06 |
1989-10-19 |
Takeda Chemical Industries Ltd |
Chemically modified lymphokine and production thereof
|
|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
US4766106A
(en)
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4704692A
(en)
|
1986-09-02 |
1987-11-03 |
Ladner Robert C |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5128257A
(en)
|
1987-08-31 |
1992-07-07 |
Baer Bradford W |
Electroporation apparatus and process
|
|
DE68925030T2
(de)
|
1988-01-21 |
1996-07-25 |
Massachusetts Inst Technology |
Molekültransport durch gewebe mit der verwendung von elektroporation.
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
|
WO1990006952A1
(fr)
|
1988-12-22 |
1990-06-28 |
Kirin-Amgen, Inc. |
Facteur de stimulation de colonies de granulocytes modifies chimiquement
|
|
US5089261A
(en)
|
1989-01-23 |
1992-02-18 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
US4902502A
(en)
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
CA2019758C
(en)
|
1990-06-25 |
2001-09-04 |
Kevin L. Firth |
Improved electroporation device and method
|
|
US5137817A
(en)
|
1990-10-05 |
1992-08-11 |
Amoco Corporation |
Apparatus and method for electroporation
|
|
US5173158A
(en)
|
1991-07-22 |
1992-12-22 |
Schmukler Robert E |
Apparatus and methods for electroporation and electrofusion
|
|
ATE207080T1
(de)
|
1991-11-25 |
2001-11-15 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
WO1993019768A1
(en)
|
1992-04-03 |
1993-10-14 |
The Regents Of The University Of California |
Self-assembling polynucleotide delivery system
|
|
US5304120A
(en)
|
1992-07-01 |
1994-04-19 |
Btx Inc. |
Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
|
|
US5273525A
(en)
|
1992-08-13 |
1993-12-28 |
Btx Inc. |
Injection and electroporation apparatus for drug and gene delivery
|
|
US5318514A
(en)
|
1992-08-17 |
1994-06-07 |
Btx, Inc. |
Applicator for the electroporation of drugs and genes into surface cells
|
|
PT672141E
(pt)
|
1992-10-23 |
2003-09-30 |
Immunex Corp |
Metodos de preparacao de proteinas oligomericas soluveis
|
|
US5631237A
(en)
|
1992-12-22 |
1997-05-20 |
Dzau; Victor J. |
Method for producing in vivo delivery of therapeutic agents via liposomes
|
|
GB9317380D0
(en)
|
1993-08-20 |
1993-10-06 |
Therexsys Ltd |
Transfection process
|
|
US5821332A
(en)
|
1993-11-03 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor on the surface of activated CD4+ T-cells: ACT-4
|
|
US6989434B1
(en)
|
1994-02-11 |
2006-01-24 |
Invitrogen Corporation |
Reagents for intracellular delivery of macromolecules
|
|
US5691188A
(en)
|
1994-02-14 |
1997-11-25 |
American Cyanamid Company |
Transformed yeast cells expressing heterologous G-protein coupled receptor
|
|
JPH11505505A
(ja)
|
1994-06-27 |
1999-05-21 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
ターゲッティングされた遺伝子輸送システム
|
|
US5908635A
(en)
|
1994-08-05 |
1999-06-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method for the liposomal delivery of nucleic acids
|
|
US5484720A
(en)
|
1994-09-08 |
1996-01-16 |
Genentech, Inc. |
Methods for calcium phosphate transfection
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
US5830430A
(en)
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
|
DK0766745T3
(da)
|
1995-04-08 |
2002-11-25 |
Lg Chemical Ltd |
Monoklonalt antistof, som er specifikt for humant 4-1BB samt cellelinje, som producerer dette
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
US5976567A
(en)
|
1995-06-07 |
1999-11-02 |
Inex Pharmaceuticals Corp. |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
US6010613A
(en)
|
1995-12-08 |
2000-01-04 |
Cyto Pulse Sciences, Inc. |
Method of treating materials with pulsed electrical fields
|
|
DE69738522T2
(de)
|
1996-08-02 |
2009-04-02 |
Bristol-Myers Squibb Co. |
Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
|
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
|
RU2192281C2
(ru)
|
1996-10-11 |
2002-11-10 |
Бристол-Маерс Сквибб Компани |
Способы и композиции для иммуномодуляции
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
CA2277278A1
(en)
|
1997-01-10 |
1998-07-16 |
Life Technologies, Inc. |
Embryonic stem cell serum replacement
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
ATE466948T1
(de)
|
1997-03-11 |
2010-05-15 |
Univ Minnesota |
Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle
|
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
US6475994B2
(en)
|
1998-01-07 |
2002-11-05 |
Donald A. Tomalia |
Method and articles for transfection of genetic material
|
|
US6312700B1
(en)
|
1998-02-24 |
2001-11-06 |
Andrew D. Weinberg |
Method for enhancing an antigen specific immune response with OX-40L
|
|
ES2341926T3
(es)
|
1998-03-02 |
2010-06-29 |
Massachusetts Institute Of Technology |
Poliproteinas con dedos de cinc que tienen enlazadores mejorados.
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
US7013219B2
(en)
|
1999-01-12 |
2006-03-14 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
US7030215B2
(en)
|
1999-03-24 |
2006-04-18 |
Sangamo Biosciences, Inc. |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US20030104526A1
(en)
|
1999-03-24 |
2003-06-05 |
Qiang Liu |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US6794136B1
(en)
|
2000-11-20 |
2004-09-21 |
Sangamo Biosciences, Inc. |
Iterative optimization in the design of binding proteins
|
|
CA2704600C
(en)
|
1999-04-09 |
2016-10-25 |
Kyowa Kirin Co., Ltd. |
A method for producing antibodies with increased adcc activity
|
|
US7189705B2
(en)
|
2000-04-20 |
2007-03-13 |
The University Of British Columbia |
Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
|
|
US6627442B1
(en)
|
2000-08-31 |
2003-09-30 |
Virxsys Corporation |
Methods for stable transduction of cells with hiv-derived viral vectors
|
|
CN1507357A
(zh)
|
2000-10-31 |
2004-06-23 |
PRҩƷ����˾ |
提高生物活性分子传递的方法和组合物
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
US7083784B2
(en)
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
|
CA2463879C
(en)
|
2001-10-25 |
2012-12-04 |
Genentech, Inc. |
Glycoprotein compositions
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
JP2006502091A
(ja)
|
2002-03-01 |
2006-01-19 |
イミューノメディクス、インコーポレイテッド |
クリアランス速度を高めるための二重特異性抗体点変異
|
|
BR0309145A
(pt)
|
2002-04-09 |
2005-02-01 |
Kyowa Hakko Kogyo Kk |
Células das quais o genoma é modificado
|
|
DE60317677T2
(de)
|
2002-06-13 |
2008-10-30 |
Crucell Holland B.V. |
Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
|
|
JP2006500921A
(ja)
|
2002-07-30 |
2006-01-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
ヒト４−１ｂｂに対するヒト化抗体
|
|
DK1534335T4
(en)
|
2002-08-14 |
2015-10-05 |
Macrogenics Inc |
FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
|
EP1553975B8
(en)
|
2002-09-27 |
2023-04-12 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
|
DK1562972T3
(da)
|
2002-10-15 |
2010-12-06 |
Facet Biotech Corp |
Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
|
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
CN101120083B
(zh)
|
2003-10-08 |
2013-03-27 |
威尔森沃尔夫制造公司 |
利用透气性材料进行细胞培养的方法及装置
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
SI1706424T1
(sl)
|
2004-01-12 |
2010-01-29 |
Applied Molecular Evolution |
Variante fc regij
|
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
EP2471813B1
(en)
|
2004-07-15 |
2014-12-31 |
Xencor, Inc. |
Optimized Fc variants
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
CA2585776A1
(en)
|
2004-10-29 |
2006-05-11 |
University Of Southern California |
Combination cancer immunotherapy with co-stimulatory molecules
|
|
DK1877090T3
(da)
|
2005-05-06 |
2014-04-14 |
Providence Health System |
Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf
|
|
US7596024B2
(en)
|
2006-07-14 |
2009-09-29 |
Semiconductor Energy Laboratory Co., Ltd. |
Nonvolatile memory
|
|
EP1894940A1
(en)
|
2006-08-28 |
2008-03-05 |
Apogenix GmbH |
TNF superfamily fusion proteins
|
|
KR20100014588A
(ko)
|
2007-02-27 |
2010-02-10 |
제넨테크, 인크. |
길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
|
|
ES2560871T3
(es)
|
2007-07-10 |
2016-02-23 |
Apogenix Gmbh |
Proteínas de fusión de colectina de la superfamilia de TNF
|
|
WO2009045457A2
(en)
|
2007-10-02 |
2009-04-09 |
Rxi Pharmaceuticals Corp. |
Tripartite rnai constructs
|
|
PT2594590E
(pt)
|
2007-12-14 |
2015-01-14 |
Bristol Myers Squibb Co |
Moléculas de ligação ao recetor humano ox40
|
|
CA2715289C
(en)
|
2008-02-11 |
2019-12-24 |
Rxi Pharmaceuticals Corporation |
Modified rnai polynucleotides and uses thereof
|
|
WO2010003766A2
(en)
|
2008-06-17 |
2010-01-14 |
Apogenix Gmbh |
Multimeric tnf receptors
|
|
ES2538122T3
(es)
|
2008-07-21 |
2015-06-17 |
Apogenix Gmbh |
Moléculas de una sola cadena de TNFSF
|
|
EP2342340A1
(en)
|
2008-09-22 |
2011-07-13 |
Rxi Pharmaceuticals Corporation |
Rna interference in skin indications
|
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
|
US8664366B2
(en)
|
2009-01-09 |
2014-03-04 |
Apogenix Gmbh |
Fusion proteins forming trimers
|
|
US8586526B2
(en)
|
2010-05-17 |
2013-11-19 |
Sangamo Biosciences, Inc. |
DNA-binding proteins and uses thereof
|
|
US20130115617A1
(en)
|
2009-12-08 |
2013-05-09 |
John R. Wilson |
Methods of cell culture for adoptive cell therapy
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
EP2510086A4
(en)
|
2009-12-08 |
2013-05-22 |
Wolf Wilson Mfg Corp |
IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES
|
|
CN103200945B
(zh)
|
2010-03-24 |
2016-07-06 |
雷克西制药公司 |
眼部症候中的rna干扰
|
|
EP3560503B1
(en)
|
2010-03-24 |
2021-11-17 |
Phio Pharmaceuticals Corp. |
Rna interference in dermal and fibrotic indications
|
|
RU2615143C2
(ru)
|
2010-03-24 |
2017-04-04 |
Адвирна |
Самодоставляющие PHKi соединения уменьшенного размера
|
|
AU2011265733B2
(en)
|
2010-06-14 |
2014-04-17 |
Iowa State University Research Foundation, Inc. |
Nuclease activity of TAL effector and Foki fusion protein
|
|
CA2809089C
(en)
|
2010-08-23 |
2018-12-18 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
|
US8962804B2
(en)
|
2010-10-08 |
2015-02-24 |
City Of Hope |
Meditopes and meditope-binding antibodies and uses thereof
|
|
WO2012065086A1
(en)
|
2010-11-12 |
2012-05-18 |
Nektar Therapeutics |
Conjugates of an il-2 moiety and a polymer
|
|
WO2012112730A2
(en)
|
2011-02-15 |
2012-08-23 |
Merrimack Pharmaceuticals, Inc. |
Compositions and methods for delivering nucleic acid to a cell
|
|
US20120244133A1
(en)
|
2011-03-22 |
2012-09-27 |
The United States of America, as represented by the Secretary, Department of Health and |
Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
|
|
CA3111953C
(en)
|
2011-04-05 |
2023-10-24 |
Cellectis |
Method for the generation of compact tale-nucleases and uses thereof
|
|
US20140234320A1
(en)
|
2011-06-20 |
2014-08-21 |
La Jolla Institute For Allergy And Immunology |
Modulators of 4-1bb and immune responses
|
|
EP2737317A2
(en)
|
2011-07-28 |
2014-06-04 |
The Trustees Of The University Of Pennsylvania |
Methods for diagnosing cancer by characterization of tumor cells associated with pleural or serous fluids
|
|
CA2845810C
(en)
|
2011-08-23 |
2017-03-28 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
CN103946952A
(zh)
|
2011-09-16 |
2014-07-23 |
宾夕法尼亚大学董事会 |
用于治疗癌症的rna改造的t细胞
|
|
PT2768942T
(pt)
|
2011-10-17 |
2020-01-21 |
Massachusetts Inst Technology |
Entrega intracelular
|
|
US9579338B2
(en)
|
2011-11-04 |
2017-02-28 |
Nitto Denko Corporation |
Method of producing lipid nanoparticles for drug delivery
|
|
EP2850175B1
(en)
|
2012-05-18 |
2020-12-16 |
Wilson Wolf Manufacturing Corporation |
Improved methods of cell culture for adoptive cell therapy
|
|
BR112014029417B1
(pt)
|
2012-05-25 |
2023-03-07 |
Cellectis |
Método ex vivo para a preparação de células t para imunoterapia
|
|
WO2013182910A2
(en)
|
2012-06-05 |
2013-12-12 |
Cellectis |
New transcription activator-like effector (tale) fusion protein
|
|
US9156897B2
(en)
|
2012-06-08 |
2015-10-13 |
Alkermes, Inc. |
Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
|
|
EP2859093A4
(en)
|
2012-06-11 |
2016-08-17 |
Wolf Wilson Mfg Corp |
IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES
|
|
EP2840140B2
(en)
|
2012-12-12 |
2023-02-22 |
The Broad Institute, Inc. |
Crispr-Cas based method for mutation of prokaryotic cells
|
|
WO2014093655A2
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
CN113355357B
(zh)
|
2012-12-12 |
2024-12-03 |
布罗德研究所有限公司 |
对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
|
|
IL239344B2
(en)
|
2012-12-12 |
2024-06-01 |
Broad Inst Inc |
Systems engineering, methods and optimal guiding components for sequence manipulation
|
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
|
EP2961415B1
(en)
|
2013-03-01 |
2021-01-06 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Methods of producing enriched populations of tumor-reactive t cells from tumor
|
|
SG10201708048XA
(en)
|
2013-03-18 |
2017-10-30 |
Biocerox Prod Bv |
Humanized anti-cd134 (ox40) antibodies and uses thereof
|
|
US11311575B2
(en)
|
2013-05-13 |
2022-04-26 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
|
CN118562610A
(zh)
|
2013-06-24 |
2024-08-30 |
威尔逊沃夫制造公司 |
用于透气性细胞培养过程的封闭系统装置和方法
|
|
CN106061488B
(zh)
|
2013-12-02 |
2021-04-09 |
菲奥医药公司 |
癌症的免疫治疗
|
|
WO2015095423A2
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
US10899840B2
(en)
|
2014-02-04 |
2021-01-26 |
Pfizer Inc. |
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
|
|
RU2739770C2
(ru)
|
2014-06-11 |
2020-12-28 |
полибайосепт ГмбХ |
Экспансия лимфоцитов с использованием композиции цитокинов для активной клеточной иммунотерапии
|
|
EP3197911A4
(en)
|
2014-09-22 |
2018-06-20 |
Intrexon Corporation |
Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
AU2016289530B2
(en)
|
2015-07-09 |
2021-05-06 |
Massachusetts Institute Of Technology |
Delivery of materials to anucleate cells
|
|
WO2017070151A1
(en)
|
2015-10-19 |
2017-04-27 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
|
|
JP7033535B2
(ja)
|
2016-01-12 |
2022-03-10 |
スクイーズ バイオテクノロジーズ カンパニー |
複合体の細胞内送達
|
|
WO2017210677A1
(en)
|
2016-06-03 |
2017-12-07 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
USE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA (PGC1α) AGONISTS TO IMPROVE EX VIVO EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS)
|
|
HUE066460T2
(hu)
|
2016-10-26 |
2024-08-28 |
Iovance Biotherapeutics Inc |
A kriokonzervált tumor infiltráló limfociták restimulációja
|
|
KR20190105568A
(ko)
|
2016-11-10 |
2019-09-17 |
넥타르 테라퓨틱스 |
종양의 면역 요법적 치료 방법
|
|
MX2019007963A
(es)
|
2017-01-06 |
2019-10-21 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf.
|
|
KR102619747B1
(ko)
|
2017-01-10 |
2023-12-29 |
넥타르 테라퓨틱스 |
Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법
|
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
KR20200003913A
(ko)
|
2017-05-10 |
2020-01-10 |
이오반스 바이오테라퓨틱스, 인크. |
액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
|
|
MY206158A
(en)
|
2017-05-24 |
2024-12-02 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
AR112072A1
(es)
*
|
2017-06-05 |
2019-09-18 |
Iovance Biotherapeutics Inc |
Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
|
|
KR20240141853A
(ko)
|
2017-08-03 |
2024-09-27 |
신톡스, 인크. |
자가면역 질환의 치료를 위한 사이토카인 접합체
|
|
CR20200251A
(es)
*
|
2017-11-17 |
2020-07-17 |
Iovance Biotherapeutics Inc |
Expansión de til de aspirados con aguja fina y biopsias por punción
|
|
EP3714041A1
(en)
*
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
EP3737743A1
(en)
|
2018-01-08 |
2020-11-18 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
WO2019210131A1
(en)
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2020096927A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
|
WO2020123716A1
(en)
|
2018-12-11 |
2020-06-18 |
Obsidian Therapeutics, Inc. |
Membrane bound il12 compositions and methods for tunable regulation
|
|
EP3923974A4
(en)
|
2019-02-06 |
2023-02-08 |
Synthorx, Inc. |
IL-2 CONJUGATES AND METHODS OF USE THEREOF
|
|
US20210038684A1
(en)
|
2019-06-11 |
2021-02-11 |
Alkermes Pharma Ireland Limited |
Compositions and Methods for Cancer Immunotherapy
|
|
WO2020252110A1
(en)
*
|
2019-06-14 |
2020-12-17 |
Bluebird Bio, Inc. |
Compositions and methods for treating cancer
|
|
EP4048295A1
(en)
*
|
2019-10-25 |
2022-08-31 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|